BPDCN – a rare, skin-tropic hematopoietic neoplasm
Our mission
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Despite affecting mostly the elderly, it can occur at any age. This peculiar hematological neoplasm is characterized by cutaneous tumor formation and subsequent (or simultaneous) leukemic manifestation. Diagnosing BPDCN can be challenging due to its rarity. Most patients respond to chemotherapy, but recurrence often happens; therefore, understanding the pathogenesis and developing effective treatments is crucial. Our mission is to contribute to the timely and correct diagnosis of BPDCN and to study its pathogenesis.
MEMBER
Kengo TAKEUCHI, MD, PhD. Hematopathologist
Assistant Director, Cancer Institute
Chief, Division of Pathology, Cancer Institute
Project Leader, Pathology Project for Molecular Targets, Cancer Institute
Center Chief, Clinical Pathology Center, Cancer Institute Hospital
Japanese Foundation for Cancer Research
Kana SAKAMOTO, MD, PhD
Pathology Project for Molecular Targets, Cancer Institute
Division of Pathology, Cancer Institute
Japanese Foundation for Cancer Research
NEWS
- 2023/07/19
- 2022/02/16
-
Publications
- 2021/10/25
-
Current Status Report
The following is a report on the cumulative number of the archived cases.
Total cases: 298
Cases with confirmed diagnosis of BPDCN: 222
(As of August 2021)Both diagnostic consultation and the research are continuing.
Please contact us if you have any applicable cases, including those in which the diagnosis of BPDCN is uncertain. - 2020/12/23
-
Publications
- 2020/02/27
-
Our website is online.
Publications
Our paper on diagnostic criteria for BPDCN is now online. This paper is available for free download for a limited time!